Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy

Mepolizumab and benralizumab are monoclonal antibodies (mAbs) approved for the treatment of severe eosinophilic asthma (SEA), targeting interleukin (IL)-5 and IL-5R, respectively [1]. In appropriately selected patients, their use leads to significant reductions in asthma exacerbations and maintenance oral corticosteroid (mOCS) dose [2, 3].

Source: European Respiratory Journal - June 10, 2021 Category: Respiratory Medicine Authors: Hearn, A. P., Hug, O. D., Somani, Z. A., Kavanagh, J., d'Ancona, G., Roxas, C., Green, L., Thomson, L., Fernandes, M., Kent, B. D., Dhariwal, J., Nanzer, A. M., Jackson, D. J. Tags: Original Articles: Research letters Source Type: research